FDA OKs Esketamine Nasal Spray Monotherapy for Depression

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults with major depressive disorder who have not responded adequately to at least two oral antidepressants. …